New protein-targeting drug shows promise in early trial for patients with high-risk CLL

May 17, 2013

A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by Dana-Farber Cancer Institute investigators. In a phase 1 clinical trial, the drug produced rapid and long-lasting tumor shrinkage in about two-thirds of patients, stalling disease progression for 17 months, on average. The activity of the drug is noteworthy, given that the patients had an average of five prior therapies.

CLL, which is often diagnosed through a routine blood test, is a slow-growing cancer and many patients do not require treatment until they start having symptoms. The vast majority of patients with CLL experience a relapse at some point after initial treatment with a combination of chemotherapy and . About 20 percent have so-called refractory disease, meaning they either relapse quickly (within six months) or do not respond to initial treatment at all. Patients in both categories are in need of better treatments, as the currently approved options have limited success.

Idelalisib is the first that selectively blocks -delta, a subtype of PI3K proteins that is overactive specifically in , and is critical for . This is the first study of a PI3K-delta inhibitor in patients with CLL.

"We are reaching a point in the treatment of CLL where we have multiple agents in development that are very effective, and drugs like idelalisib are probably going to change the landscape of the disease in the next few years," said the study's lead author Jennifer R. Brown, MD, PhD, director of the Center at Dana-Farber.

"While this research is still early and ongoing, we hope this drug, along with others like it, will lead to prolonged survival and eventually help turn CLL into a condition that is treated like , where a patient can take a couple of pills every day," Brown added. "In the shorter term, these drugs may also provide an alternative to chemotherapy in elderly patients who tend not to tolerate chemotherapy well."

The clinical trial included 54 patients with refractory or relapsed CLL who received idelalisib. The patients' cancer had worsened despite having been treated with a median of five prior therapies. Once idelalisib treatment began, tumor reduction with a decrease in symptoms was rapid, generally occurring within two months, and was observed in about two-thirds of patients.

The 17-month average period in which the disease was held in check was better than the six- to 12-month benefit that might typically be expected for a sixth-line therapy. Patients who benefited from the drug were offered the opportunity to continue treatment on an extension study.

The researchers reported that side effects were manageable; only seven percent of patients discontinued treatment due to treatment-related effects.

Explore further: Leap in leukemia treatment reported by Dartmouth researchers

Related Stories

Leap in leukemia treatment reported by Dartmouth researchers

May 13, 2013
Doctors at Dartmouth-Hitchcock's Norris Cotton Cancer Center (NCCC) have found a combination of drugs to potentially treat chronic lymphocytic leukemia (CLL) more effectively. The research was published online on May 3, 2013, ...

Older and younger chronic leukemia patients may need different therapy

December 12, 2012
Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur ...

Monoclonal antibody targets, kills leukemia cells

March 25, 2013
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.

Updated clinical results show experimental agent ibrutinib as highly active in CLL patients

December 9, 2012
Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...

Experimental agent may help older people with chronic leukemia

May 16, 2012
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.

Drug combination acts against aggressive chronic lymphocytic leukemia

December 10, 2012
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.